Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Movymia

- PMLiVE

Merck & Co’s oral hepatitis C therapy approved in US

Fixed-dose combination Zepatier wins a licence from the FDA

Eli Lilly HQ

Eli Lilly files oral rheumatoid arthritis drug baricitinib in US

Hopes for approval later this year after the drug outperformed Humira in trials

- PMLiVE

Germany’s Merck triumphs in court battle with US namesake

English court rules Merck & Co breached the firms' naming agreement

Sanofi reception

Sanofi and Novartis snap up immuno-oncology candidates

Separate licensing deals see the firms look to catch up with the category's leaders

- PMLiVE

Mylan buys into six biosimilars, including Orencia candidate

Deal with Momenta bolsters biosimilars pipeline for new products

Roche Basel Switzerland

Roche prepares to file atezolizumab for bladder cancer

Imminent submission to the FDA after additional positive phase II trial results

- PMLiVE

Sanofi abandons inhaled insulin pact with Mannkind

Poor sales prompt return of Afrezza rights less than a year after its launch

Biosimilars in 2018: EU doctors’ perceptions of RA drug market

Published in pharmaphorum October 2015 by Laurent Chanroux

Research Partnership

Sanofi reception

Sanofi uses priority review voucher for diabetes combo

LixiLan in race with Xultophy in bid to hit US market first

- PMLiVE

Boehringer plans €500m biopharma expansion in Austria

New production facility in Vienna will create 400 jobs when it comes online in 2021

- PMLiVE

Keytruda bounces back in rivalry with Opdivo

First drug in its class to secure FDA approval as a first-line therapy for malignant melanoma

EU flag

Nine positive opinions for new drugs at CHMP meeting

Tagrisso, Zurampic and Portrazza among the latest recommendations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links